Last updated: 10 July 2019 at 2:32am EST

Kenneth S Boger Net Worth




The estimated Net Worth of Kenneth S Boger is at least $65.4 Million dollars as of 13 September 2011. Kenneth Boger owns over 22,000 units of Vertex Pharmaceuticals stock worth over $64,089,425 and over the last 21 years Kenneth sold VRTX stock worth over $1,357,708.

Kenneth Boger VRTX stock SEC Form 4 insiders trading

Kenneth has made over 17 trades of the Vertex Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. Most recently Kenneth exercised 22,000 units of VRTX stock worth $412,500 on 13 September 2011.

The largest trade Kenneth's ever made was exercising 22,000 units of Vertex Pharmaceuticals stock on 13 September 2011 worth over $412,500. On average, Kenneth trades about 4,359 units every 75 days since 2003. As of 13 September 2011 Kenneth still owns at least 134,999 units of Vertex Pharmaceuticals stock.

You can see the complete history of Kenneth Boger stock trades at the bottom of the page.



What's Kenneth Boger's mailing address?

Kenneth's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.



What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.



What does Vertex Pharmaceuticals's logo look like?

Vertex Pharmaceuticals, Inc. logo

Complete history of Kenneth Boger stock trades at Vertex Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Sep 2011 Kenneth S Boger
SVP and General Counsel
Option 22,000 $18.75 $412,500
13 Sep 2011
134,999
29 Jul 2011 Kenneth S Boger
SVP and General Counsel
Option 7,334 $18.75 $137,513
29 Jul 2011
120,333
20 Jul 2011 Kenneth S Boger
SVP and General Counsel
Option 7,333 $18.75 $137,494
20 Jul 2011
120,332
13 Jul 2011 Kenneth S Boger
SVP and General Counsel
Option 7,334 $18.75 $137,513
13 Jul 2011
120,333
6 Jul 2011 Kenneth S Boger
SVP and General Counsel
Option 7,333 $18.75 $137,494
6 Jul 2011
120,332
29 Jun 2011 Kenneth S Boger
SVP and General Counsel
Option 7,334 $18.75 $137,513
29 Jun 2011
120,333
28 Jun 2011 Kenneth S Boger
SVP and General Counsel
Option 14,667 $18.75 $275,006
28 Jun 2011
127,666
8 Jun 2011 Kenneth S Boger
SVP and General Counsel
Option 7,333 $18.75 $137,494
8 Jun 2011
120,332
1 Jun 2011 Kenneth S Boger
SVP and General Counsel
Option 7,334 $18.75 $137,513
1 Jun 2011
120,333
25 May 2011 Kenneth S Boger
SVP and General Counsel
Sale 4,066 $55.97 $227,574
25 May 2011
112,999
2 May 2011 Kenneth S Boger
SVP and General Counsel
Option 5,000 $24.66 $123,300
2 May 2011
121,752
7 May 2009 Kenneth S Boger
SVP and General Counsel
Sale 11,826 $28.89 $341,653
7 May 2009
95,857
18 Nov 2008 Kenneth S Boger
SVP and General Counsel
Sale 15,000 $26.69 $400,350
18 Nov 2008
97,517
7 May 2007 Kenneth S Boger
SVP and General Counsel
Sale 12,684 $30.60 $388,130
7 May 2007
103,677
30 Apr 2007 Kenneth S Boger
SVP and General Counsel
Option 12,000 $10.41 $124,920
30 Apr 2007
128,361
30 Mar 2007 Kenneth S Boger
SVP and General Counsel
Option 11,700 $9.07 $106,119
30 Mar 2007
128,061
17 Nov 2003 Kenneth S Boger
SVP and General Counsel
Buy 5,360 $8.87 $47,543
17 Nov 2003
19,000


Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: